Review
Oncology
Rajiv Shah, Laura V. Klotz, Julia Glade
Summary: Pleural mesothelioma is an aggressive malignant tumor associated with asbestos exposure. Current treatment options mainly include platinum-based chemotherapy, while recent developments in combination therapy have shown improvements. Researchers are working on developing more effective, tolerable, and affordable drugs to tackle the expected increase in disease burden.
Article
Oncology
Rossella Bruno, Anello Marcello Poma, Greta Ali, Agnese Proietti, Alessandro Ribechini, Antonio Chella, Gabriella Fontanini
Summary: The validation of a 117-gene expression panel as a diagnostic tool for pleural mesothelioma (PM) cytological diagnosis was conducted in this study. The gene panel proved to be useful in differentiating PM and mesothelial hyperplasia, as well as distinguishing between PM subtypes. It has the potential to improve the clinical management of PM patients.
Article
Oncology
Arnulf Holzknecht, Oliver Illini, Maximilian J. Hochmair, Dagmar Krenbek, Ulrike Setinek, Florian Huemer, Erwin Bitterlich, Christoph Kaindl, Vladyslav Getman, Ahmet Akan, Michael Weber, Gunther Leobacher, Arschang Valipour, Michael R. Mueller, Stefan B. Watzka
Summary: An analysis of 112 patients with malignant pleural mesothelioma found that combined chemotherapy and surgery, epithelioid tumor subtype, early tumor stage, and the absence of relevant comorbidities were favorable factors for survival. The best treatment approach for this cancer should involve multiple therapeutic approaches.
Article
Oncology
Hely Ollila, Mikko I. Mayranpaa, Lassi Paavolainen, Juuso Paajanen, Katja Valimaki, Eva Sutinen, Henrik Wolff, Jari Rasanen, Olli Kallioniemi, Marjukka Myllarniemi, Ilkka Ilonen, Teijo Pellinen
Summary: High-resolution single-cell spatial profiling of the tumor immune microenvironment (TIME) in mesothelioma can help identify patient subgroups with long survival and potential immunophenotypes for novel treatment strategies. CD11c(+) cells stood out as the most potential prognostic cell subtype, adding prediction power to clinical factors.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Umair Ali Khan Saddozai, Fengling Wang, Saadullah Khattak, Muhammad Usman Akbar, Muhammad Badar, Nazeer Hussain Khan, Lu Zhang, Wan Zhu, Longxiang Xie, Yongqiang Li, Xinying Ji, Xiangqian Guo
Summary: This study identified two distinct epithelioid malignant pleural mesothelioma subtypes with different gene expression patterns. Each subtype has different clinicopathological characteristics and molecular pathways, providing insights for the clinical applications and advanced mechanisms of eMPM.
Article
Oncology
Laura V. Klotz, Hans Hoffmann, Rajiv Shah, Florian Eichhorn, Christiane Gruenewald, Elena L. Bulut, Raffaella Griffo, Thomas Muley, Petros Christopoulos, Philip Baum, Peter Huber, Seyer Safi, Marc Kriegsmann, Michael Thomas, Helge Bischoff, Hauke Winter, Martin E. Eichhorn
Summary: This study analyzed a 20-year experience of surgery for malignant pleural mesothelioma (MPM) and found that extended pleurectomy/decortication combined with hyperthermic intrathoracic chemoperfusion and adjuvant chemotherapy resulted in higher overall survival compared to trimodal extrapleural pneumonectomy (EPP). The perioperative morbidity was also lower in the surgery group.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Seiki Hasegawa, Kohei Yokoi, Morihito Okada, Fumihiro Tanaka, Mototsugu Shimokawa, Takashi Daimon, Takashi Nakano
Summary: Neoadjuvant chemotherapy followed by pleurectomy/decortication is feasible and provides acceptable survival rates and low mortality/morbidity in the treatment of malignant pleural mesothelioma.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2022)
Article
Chemistry, Multidisciplinary
Min-Sung Kang, Sung-Soo Lee, Soon-Chan Kwon, Da-An Huh, Yong-Jin Lee
Summary: This study aimed to identify the epidemiologic characteristics and prognostic factors for malignant pleural mesothelioma in Korea. The results showed that a combination of surgery and chemotherapy was a significant predictor of survival, while factors like sex, age, smoking history, occupational asbestos exposure, and histological subtype had no significant impact on prognosis. The study also found that non-occupational exposure had a similar prognosis to occupational asbestos exposure, and there was no sex difference in survival rates.
APPLIED SCIENCES-BASEL
(2021)
Review
Medicine, General & Internal
Sam M. Janes, Doraid Alrifai, Dean A. Fennell
Summary: Mesothelioma, mostly caused by asbestos exposure, has a decreasing incidence but high mortality due to late diagnosis and treatment resistance. Pemetrexed-cisplatin and immune checkpoint inhibitors have shown modest survival extension.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Seiki Hasegawa, Yasushi Shintani, Teruhisa Takuwa, Keisuke Aoe, Katsuya Kato, Nobukazu Fujimoto, Yasuhiro Hida, Masahiro Morise, Yasumitsu Moriya, Takao Morohoshi, Hidemi Suzuki, Masayuki Chida, Shunsuke Endo, Mitsutaka Kadokura, Meinoshin Okumura, Satoshi Hattori, Hiroshi Date, Ichiro Yoshino
Summary: A nationwide prospective registry for newly diagnosed and untreated pleural mesothelioma in Japan was conducted, and data on patients' survival were collected. The study found that surgery significantly prolonged overall survival, and tumor shape and thickness were important prognostic factors.
Article
Oncology
Margherita Vannucchi, Veronica Pennati, Clelia Mencaroni, Chiara Defraia, Ledi Bardhi, Francesca Castiglione, Cristiana Bellan, Camilla Eva Comin
Summary: Malignant pleural mesothelioma (MPM) is a aggressive malignancy of the pleural surface that includes three major histologic subtypes: epitheliod, sarcomatoid, and biphasic. KRAS mutations and the occurrence of ≥3 mutations were associated with shortened median survival, while the presence of KDR single nucleotide polymorphism p.V297I was associated with a favorable variable for survival. These findings contribute to the understanding of the mutation profile of MPM and the impact of selected somatic mutations and KDR polymorphism on prognosis.
Article
Medicine, General & Internal
Francesco Fortarezza, Mila Della Barbera, Federica Pezzuto, Francesca Lunardi, Eleonora Faccioli, Giulia Pasello, Federico Rea, Stefania Rizzo, Fiorella Calabrese
Summary: The histological diagnosis of pleural epithelioid mesothelioma can be challenging in cases of rare variants or patients with previous or concomitant tumors. Immunohistochemical reactions play a role in obtaining a sensitive and specific diagnosis of malignant pleural mesothelioma but sometimes the final interpretation remains inconclusive. Ultrastructural examination has historically been a useful tool in defining the mesothelial nature of neoplastic cells.
Review
Oncology
Wanyuan Cui, Sanjay Popat
Summary: Pleural mesothelioma (PM) treatment includes combination chemotherapy, immunotherapy, and targeted therapy. Ipilimumab-nivolumab as a new first-line treatment standard has shown improved overall survival, but current challenges include understanding the role of combination treatments, treatment resistance mechanisms, and establishing predictive biomarkers.
CANCER TREATMENT REVIEWS
(2021)
Article
Instruments & Instrumentation
Liang Yang, Hanghang Fang, Jingjing Jiang, Yongjie Sha, Zhiyuan Zhong, Fenghua Meng
Summary: This study presents a novel approach to treat malignant pleural mesothelioma by using EGFR-CPs-PEM to enhance the anticancer activity of PEM, showing superior tumor deposition and penetration compared to CPs-PEM and free PEM. This method enables more efficient drug delivery and more potent anticancer effects.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2022)
Article
Medicine, General & Internal
Rossella Bruno, Anello Marcello Poma, Greta Ali, Claudia Distefano, Agnese Proietti, Antonio Chella, Marco Lucchi, Franca Melfi, Renato Franco, Gabriella Fontanini
Summary: The study aimed to identify markers for biphasic pleural mesothelioma (PM) in order to improve subtyping and prognosis definition. By comparing the expression levels of cancer genes in the three major histotypes and evaluating the expression differences within biphasic PM, potential markers for diagnosis and prognostic stratification were identified.
Review
Health Care Sciences & Services
J. Isabelle Choi, Jana Fox, Richard Bakst, Shaakir Hasan, Robert H. Press, Arpit M. Chhabra, Brian Yeh, Charles B. Simone, Oren Cahlon
Summary: Partial breast irradiation (PBI) delivered with proton therapy offers a shorter treatment duration and reduced toxicities, targeting less non-target breast tissue and limiting unnecessary radiation dose to thoracic organs. Proton therapy is a precision radiotherapy technology that further limits normal tissue exposure to improve quality of life for early stage breast cancer patients.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Minglei Kang, Shouyi Wei, J. Isabelle Choi, Charles B. Simone, Haibo Lin
Summary: This study focuses on quantifying the dose rate of organs-at-risk and targets based on three proposed proton PBS dose rate metrics, showing significant impact of differences in dose rate metrics on the assessment of organ-at-risk dose rate, posing challenges to the clinical implementation of FLASH. Additional investigations are needed to explore the correlation between FLASH efficacy and the dose rate metrics in proton PBS therapy.
Article
Oncology
Shouyi Wei, Haibo Lin, J. Isabelle Choi, Charles B. Simone, Minglei Kang
Summary: This study compares the performance of single-energy Bragg peak proton beams with transmission proton beams in lung tumor treatment planning, finding that Bragg peak plans achieve superior dosimetry performances in OARs while maintaining comparable dose rate performances. Beam angle optimization further improves OAR dosimetry parameters without compromising the 3D FLASH dose rate coverage.
Review
Oncology
Jana M. Kobeissi, Charles B. Simone, Haibo Lin, Lara Hilal, Carla Hajj
Summary: Radiation therapy plays a central role in the management of pancreatic cancer, and proton therapy is an emerging treatment modality. Proton irradiation remains a challenge in radiation therapy, but no significant differences in oncologic outcomes and toxicity rates have been shown compared to photon radiation treatment.
Review
Oncology
Jana M. Kobeissi, Charles B. Simone, Lara Hilal, Abraham J. Wu, Haibo Lin, Christopher H. Crane, Carla Hajj
Summary: Radiation treatment is crucial in managing luminal gastrointestinal cancers, particularly esophageal and anorectal cancers. Proton therapy is gaining interest for its ability to decrease dose to nearby organs at risk. In esophageal cancer, protons have shown superior dosimetric characteristics in sparing organs at risk, but clinical significance is conflicting. However, evidence suggests that protons offer similar or improved oncologic outcomes with reduced toxicity compared to photons. In anorectal cancers, proton therapy has shown improved organ sparing, but clinical data is limited and toxicity benefits have not been clinically proven.
Review
Oncology
Jana M. Kobeissi, Lara Hilal, Charles B. Simone, Haibo Lin, Christopher H. Crane, Carla Hajj
Summary: This review provides a concise and comprehensive summary on the use of proton therapy in the management of hepatocellular carcinoma (HCC). Proton radiation therapy plays a central role in the treatment of HCC, and evidence suggests it may be superior to photons in terms of survival and toxicity outcomes.
Article
Oncology
Beatriz E. Amendola, Anand Mahadevan, Jesus Manuel Blanco Suarez, Robert J. Griffin, Xiaodong Wu, Naipy C. Perez, Daniel S. Hippe, Charles B. Simone Ii, Majid Mohiuddin, Mohammed Mohiuddin, James W. Snider, Hualin Zhang, Quynh-Thu Le, Nina A. Mayr
Summary: SFRT shows promising potential as a new treatment modality for challenging tumors. However, the development of clinical trials is hindered by the variability in SFRT methods and the unfamiliarity with heterogeneous dosing, requiring a broad consensus.
Article
Medicine, General & Internal
Rulon Mayer, Baris Turkbey, Peter L. Choyke, Charles B. Simone
Summary: This study predicts the risk of clinically significant prostate cancer (CsPCa) and correlates it with the ISUP grade using processed SCR derived from SRBP-MRI. The results show a high correlation between SCR values and ISUP grade and CsPCa/CiPCa, indicating the potential of SRBP-MRI in non-invasive management of prostate cancer.
Article
Oncology
Michael Pennock, Shouyi Wei, Chingyun Cheng, Haibo Lin, Shaakir Hasan, Arpit M. Chhabra, J. Isabelle Choi, Richard L. Bakst, Rafi Kabarriti, Charles B. Simone II, Nancy Y. Y. Lee, Minglei Kang, Robert H. Press
Summary: Bragg peak proton FLASH is a novel radiotherapy technique that combines ultra-high dose rates and conformal organ sparing for cancer treatment. By modifying the planning software and treatment delivery, Bragg peak FLASH can improve organ sparing and target coverage compared to conventional proton therapy. This study demonstrates the potential benefits of Bragg peak proton FLASH in head and neck reirradiation.
Article
Oncology
Grant Lattery, Tyler Kaulfers, Chingyun Cheng, Xingyi Zhao, Balaji Selvaraj, Haibo Lin, Charles B. Simone II, J. Isabelle Choi, Jenghwa Chang, Minglei Kang
Summary: This study focused on developing ultra-high dose rate intensity-modulated proton therapy (IMPT) for hypofractionated treatment of early-stage breast cancer. The results showed that the Bragg peak FLASH-RT technique achieved comparable plan quality to conventional IMPT, demonstrating the feasibility of early-stage breast cancer clinical applications.
Article
Oncology
Pingfang Tsai, Yu-Lun Tseng, Brian Shen, Christopher Ackerman, Huifang A. Zhai, Francis Yu, Charles B. Simone II, J. Isabelle Choi, Nancy Y. Lee, Rafi Kabarriti, Stanislav Lazarev, Casey L. Johnson, Jiayi Liu, Chin-Cheng Chen, Haibo Lin
Summary: This study evaluates the potential of cone-beam computed tomography (CBCT)-based synthetic CT (sCT) as an alternative to verification CT (vCT) in proton therapy for enhanced treatment monitoring and early adaptation. The study found that sCT agreed with vCT in regions of homogeneous tissues, but discrepancies were observed in the thorax and abdomen. The study also observed outliers in sCT plans when there was an anatomy change or in low-density regions. The target coverage variance in most sCT cases compared to vCT was less than 5%. The study concludes that the use of sCT allows for precise treatment and prompt early adaptation in proton therapy, but quality assurance of sCT is crucial in the early stages of clinical implementation.
Article
Medicine, General & Internal
Rulon Mayer, Baris Turkbey, Peter L. Choyke, Charles B. Simone
Summary: This study aims to assess tumor aggressiveness through analysis of bi-parametric MRI images using methods like signal to clutter ratio. The results show that the processed tumor eccentricity and volume computations from spatially registered BP-MRIs have a significant correlation with the ISUP grade.
Article
Cardiac & Cardiovascular Systems
Vivek Verma, Rodney E. Wegner, Sebastian Adeberg, Zachary D. Horne, Surbhi Grover, Joseph S. Friedberg, Charles B. Simone
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Alexandra D. Dreyfuss, Pegah Jahangiri, Charles B. Simone, Abass Alavi
Article
Radiology, Nuclear Medicine & Medical Imaging
Stephanie R. Rice, Michael Chuong, Antony Koroulakis, Osman M. Siddiqui, Ankur M. Sharma, Charles B. Simone, Jason K. Molitoris, Adeel Kaiser
